The aim of the study was to examine the levels of human β-chorionic gonadotropin (β-hCG) and inhibin A, as prognostic criteria for the development of early pre-eclampsia at 16–18 weeks of pregnancy. Materials and Methods. The prospective study included 60 patients with singlet pregnancies who underwent their first prenatal screening at 11–13 weeks. The patients were selected from 300 patients using continuous sampling method. According to the gestation course and outcome, the patients were divided into 2 groups: group 1 included 45 women with uncomplicated birth, group 2 consisted of 15 women with pre-eclampsia which developed before the 34th week. Based on calculations of the individual pre-eclampsia risks up to the 34th week of pregnancy according to the results of Astraia program (>1:300), women at 16–18 weeks of pregnancy underwent additional examination to determine inhibin A and β-hCG. Results. In both groups, burdened obstetric and somatic anamnesis prevailed. Uterus fibroids and cervical ectopia were significantly more common in women with pre-eclampsia, developed up to the 34th week of pregnancy. Moreover, the threatened miscarriage prevailed in the second trimester. In the group with pre-eclampsia developed up to the 34th week, β-hCG and inhibin A values were, respectively, >35 ng/ml and >260 pg/ml. The indicators were significantly higher than in the uncomplicated birth group. Conclusions. The individual risk of preeclampsia calculated according to the Astraia program up to the 34th week of pregnancy (>1:300) and elevated levels of inhibin A and β-hCG can be considered the predictors of the early pre-eclampsia development. Keywords: early pre-eclampsia, inhibin A, human β-chorionic gonadotropin.